1142096-06-7
1142096-06-7
Chemical Structure
Etravirine-d8
- CAS No.: 1142096-06-7
- Formula:C20H9D6BrN6O
- Molecular Weight:443.33
IUPAC Name: 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)pyrimidin-4-yl)oxy)-3,5-bis(methyl-d3)benzonitrile
InChIKey: PYGWGZALEOIKDF-WFGJKAKNSA-N
SMILES: O(C1=NC(NC2=CC=C(C#N)C=C2)=NC(N)=C1Br)C3=C(C([2H])([2H])[2H])C=C(C#N)C=C3C([2H])([2H])[2H]
Biological Activity: Etravirine-d8 is the deuterium labeled Etravirine. Etravirine (R165335) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Etravirine-d8 | Etravirine-d8 is the deuterium labeled Etravirine. Etravirine (R165335) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Etravirine (Standard) | ≥98% | Etravirine (Standard) is the analytical standard of Etravirine. This product is intended for research and analytical applications. Etravirine (R165335; TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Etravirine-d4 | 98.31% | Etravirine-d4 is the deuterium labeled Etravirine. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Etravirine-13C3 | Etravirine-13C3 (R165335-13C3) is the 13C-labeled Etravirine (HY-90005). Etravirine (R165335; TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Etravirine | 99.07% | Etravirine (R165335; TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Andries, K., et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother, 2004. 48(12): p. 468 [Content Brief]
